Femur length anomalies tend to decrease with later phenology (greater day of year of adulthood anomaly) regardless of elevation or species’ seasonal timing. by César R. Nufio (11646271)

Unadjusted mean (SD) volume (ml) of beer sold per day, overall and by serving size, and volume of wine (ml) sold of premises included in primary analysis (<i>n</i> = 12). by Eleni Mantzari (6991172)

Subjects:

Heteroscedastic linear mixed model main results, estimating the volume (ml) of beer sold per day on the transformed (cube root) scale, on the original scale and on the relative sca... by Eleni Mantzari (6991172)

Subjects:

Average days (mean) to heal a wound in 2022 and 2023. by Heba Tallah Mohammed (2822432)

Association between the mean of the daily mean temperatures for the previous 7 days and AAD onset by subset analysis. by Ayami Ishikawa (19838027)

Subjects:

Cronbach’s alpha and means the stigma of Suicide Scale Short Form (SOSS-SF). by Orrin D. Ware (14829115)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Mean cocaine consumed (mg/kg) over 10 days. by Christopher Rowan (21499924)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Global Land Use Change Impacts on Soil Nitrogen Availability and Environmental Losses by Jing Wang (6206297)

Subjects:

Comparison of mean days of wound healing across different wound types by healing durations in 2022 and 2023. by Heba Tallah Mohammed (2822432)

Adjusted mean length of stay stratified by Admission Day and COVID period. by Rajkumar Rajendram (22505442)

Decision curve analysis on day 0 (a), day 4 (b), day 8 (c), and day 13 (d) (fullPIERS model). by Guiyou Yang (10259597)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

“…Anti-nucleocapsid response was similar at day 28 (mean difference in S/C ratio: 0.02 [95%CI: −0.11, 0.15], p = 0.75) and day 90 (mean difference in S/C ratio: 0.08 [95% CI: −0.05, 0.21], p = 0.22). …”